Systematic review: Pharmacological treatment of tic disorders - Efficacy of antipsychotic and alpha-2 adrenergic agonist agents

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 6, 2013, Pages 1162-1171

  Weisman, Hannah ^a   Qureshi, Imraan A ^b   Leckman, James F ^a   Scahill, Lawrence ^b   Bloch, Michael H ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha 2 adrenergic agonist; Antipsychotic agents; Attention deficit hyperactivity disorder; Meta analysis; Tic disorders

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; GUANFACINE; HALOPERIDOL; NEUROLEPTIC AGENT; PIMOZIDE; PLACEBO; RISPERIDONE; ZIPRASIDONE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDIARRHEAL AGENT;

AGE; ATTENTION DEFICIT DISORDER; CLINICAL EFFECTIVENESS; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; GILLES DE LA TOURETTE SYNDROME; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TIC; ANIMAL; CLINICAL TRIAL (TOPIC); MEDLINE; META ANALYSIS (TOPIC); STATISTICS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMPLICATION; STATISTICS AND NUMERICAL DATA; TIC DISORDERS;

ADRENERGIC ALPHA-AGONISTS; AGE FACTORS; ANIMALS; ANTIDIARRHEALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CLINICAL TRIALS AS TOPIC; HUMANS; META-ANALYSIS AS TOPIC; PUBMED; TIC DISORDERS;

EID: 84891891769     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2012.09.008     Document Type: Review

References (59)

1. Arnsten A.F. The use of alpha-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Review of Neurotherapeutics 2010, 10(10):1595-1605.
2. Biostat Comprehensive Meta-Analysis 2005, Biostat, Englewood, NJ. 2nd ed.
3. Bloch M.H. Emerging treatments for Tourette's disorder. Current Psychiatry Reports 2008, 10(4):323-330.
4. Bloch M.H., Panza K.E., Landeros-Weisenberger A., Leckman J.F. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2009, 48(9):884-893.
5. Bloch M.H., Peterson B.S., Scahill L., Otka J., Katsovich L., Zhang H., et al. Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Archives of Pediatrics and Adolescent Medicine 2006, 160(1):65-69.
6. Bruggeman R., van der Linden C., Buitelaar J.K., Gericke G.S., Hawkridge S.M., Temlett J.A. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. Journal of Clinical Psychiatry 2001, 62(1):50-56.
7. Connor D.F., Fletcher K.E., Swanson J.M. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1999, 38(12):1551-1559.
8. Cummings D.D., Singer H.S., Krieger M., Miller T.L., Mahone E.M. Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clinical Neuropharmacology 2002, 25(6):325-332.
9. Deeks J., Higgins J., Altman D. Cochrane Reviewers' Handbook 4.2.1 2003, John Wiley & Sons, Ltd., Chichester, UK.
10. Dion Y., Annable L., Sandor P., Chouinard G. Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 2002, 22(1):31-39.
11. DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 2000, American Psychiatric Association, Washington, DC.
12. Du Y.S., Li H.F., Vance A., Zhong Y.Q., Jiao F.Y., Wang H.M., et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Australian and New Zealand Journal of Psychiatry 2008, 42(9):807-813.
13. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
14. Ercan-Sencicek A.G., Stillman A.A., Ghosh A.K., Bilguvar K., O'Roak B.J., Mason C.E., et al. l-Histidine decarboxylase and Tourette's syndrome. New England Journal of Medicine 2010, 362(20):1901-1908.
15. Erenberg G., Cruse R.P., Rothner A.D. The natural history of Tourette syndrome: a follow-up study. Annals of Neurology 1987, 22(3):383-385.
16. Fernandez T.V., Sanders S.J., Yurkiewicz I.R., Ercan-Sencicek A.G., Kim Y.S., Fishman D.O., et al. Rare copy number variants in Tourette syndrome disrupt genes in histaminergic pathways and overlap with autism. Biological Psychiatry 2012, 71(5):392-402.
17. Gaffney G.R., Perry P.J., Lund B.C., Bever-Stille K.A., Arndt S., Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41(3):330-336.
18. Gilbert D.L., Batterson J.R., Sethuraman G., Sallee F.R. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. Journal of the American Academy of Child and Adolescent Psychiatry 2004, 43(2):206-214.
19. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends in Neurosciences 1990, 13(7):244-254.
20. Harcherik D.F., Leckman J.F., Detlor J., Cohen D.J. A new instrument for clinical studies of Tourette's syndrome. Journal of the American Academy of Child Psychiatry 1984, 23(2):153-160.
21. Kang H., Zhang Y.F., Jiao F.Y., Guo X.Y., Gao X.M. Efficacy of clonidine transdermal patch for treatment of Tourette's syndrome in children. Zhongguo Dang Dai Er Ke Za Zhi 2009, 11(7):537-539.
22. Khalifa N., von Knorring A.L. Psychopathology in a Swedish population of school children with tic disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2006, 45(11):1346-1353.
23. Leckman J.F., Hardin M.T., Riddle M.A., Stevenson J., Ort S.I., Cohen D.J. Clonidine treatment of Gilles de la Tourette's syndrome. Archives of General Psychiatry 1991, 48(4):324-328.
24. Leckman J.F., Riddle M.A., Hardin M.T., Ort S.I., Swartz K.L., Stevenson J., et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. Journal of the American Academy of Child and Adolescent Psychiatry 1989, 28(4):566-573.
25. Leckman J.F., Zhang H., Vitale A., Lahnin F., Lynch K., Bondi C., et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998, 102(1 Pt 1):14-19.
26. Leon A.C. Comparative effectiveness clinical trials in psychiatry: superiority. Noninferiority and the role of active comparators. Journal of Clinical Psychiatry 2011, 72:1344-1349.
27. Liu Y.Y., Chen Y.H., Chen H., Liu Z.S. A control study of aripiprazole and tiapride treatment for tic disorders in children. Zhongguo Dang Dai Er Ke Za Zhi 2010, 12(6):421-424.
28. Lyon G.J., Samar S.M., Conelea C., Trujillo M.R., Lipinski C.M., Bauer C.C., et al. Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder. Journal of Child and Adolescent Psychopharmacology 2010, 20(4):283-289.
29. Marsh R., Maia T.V., Peterson B.S. Functional disturbances within frontostriatal circuits across multiple childhood psychopathologies. American Journal of Psychiatry 2009, 166(6):664-674.
30. Moher D., Jadad A.R., Nichol G., Penman M., Tugwell P., Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Controlled Clinical Trials 1995, 16(1):62-73.
31. Moncrieff J., Churchill R., Drummond C., McGuire H. Development of a quality assessment instrument for trials of treatments for depression and neurosis. International Journal of Methods in Psychiatric Research 2001, 10:126-133.
32. Muller-Vahl K.R., Schneider U., Prevedel H., Theloe K., Kolbe H., Daldrup T., et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. Journal of Clinical Psychiatry 2003, 64(4):459-465.
33. Onofrj M., Paci C., D'Andreamatteo G., Toma L. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. Journal of Neurology 2000, 247(6):443-446.
34. Peterson B.S., Skudlarski P., Anderson A.W., Zhang H., Gatenby J.C., Lacadie C.M., et al. A functional magnetic resonance imaging study of tic suppression in Tourette syndrome. Archives of General Psychiatry 1998, 55(4):326-333.
35. Piacentini J., Woods D.W., Scahill L., Wilhelm S., Peterson A.L., Chang S., et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA 2010, 303(19):1929-1937.
36. Pringsheim T., Marras C. Pimozide for tics in Tourette's syndrome. Cochrane Database of Systematic Reviews 2009, (2):CD006996.
37. Pringsheim T., Doja A., Gorman D., McKinlay D., Day L., Billinghurst L., et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Canadian Journal of Psychiatry 2012, 57(3):133-143.
38. Roessner V., Plessen K.J., Rothenberger A., Ludolph A.G., Rizzo R., Skov L., et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. European Child and Adolescent Psychiatry 2011, 20(4):173-196.
39. Roessner V., Schoenefeld K., Buse J., Bender S., Ehrlich S., Munchau A. Pharmacological treatment of tic disorders and Tourette syndrome. Neuropharmacology 2012.
40. Ross M.S., Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. American Journal of Psychiatry 1978, 135(5):585-587.
41. Sallee F.R., Kurlan R., Goetz C.G., Singer H., Scahill L., Law G., et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. Journal of the American Academy of Child and Adolescent Psychiatry 2000, 39(3):292-299.
42. Sallee F.R., Nesbitt L., Jackson C., Sine L., Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. American Journal of Psychiatry 1997, 154(8):1057-1062.
43. Scahill L., Chappell P.B., Kim Y.S., Schultz R.T., Katsovich L., Shepherd E., et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. American Journal of Psychiatry 2001, 158(7):1067-1074.
44. Scahill L., Erenberg G., Berlin C.M., Budman C., Coffey B.J., Jankovic J., et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006, 3(2):192-206.
45. Scahill L., Leckman J.F., Schultz R.T., Katsovich L., Peterson B.S. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60(7):1130-1135.
46. Shapiro E., Shapiro A.K., Fulop G., Hubbard M., Mandeli J., Nordlie J., et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Archives of General Psychiatry 1989, 46(8):722-730.
47. Shapiro A.K., Shapiro E.S., Young J.G. Signs, symptoms and clinical course. Gilles de la Tourette Syndrome 1988, 127-193. Raven Press, New York. 2nd ed. A.K. Shapiro, E.S. Shapiro, J.G. Young (Eds.).
48. Shaw P., Eckstrand K., Sharp W., Blumenthal J., Lerch J.P., Greenstein D., et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(49):19649-19654.
49. Singer H.S. Treatment of tics and Tourette syndrome. Current Treatment Options in Neurology 2010, 12(6):539-561.
50. Singer H.S., Brown J., Quaskey S., Rosenberg L.A., Mellits E.D., Denckla M.B. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995, 95(1):74-81.
51. Singer H.S., Morris C., Grados M. Glutamatergic modulatory therapy for Tourette syndrome. Medical Hypotheses 2010, 74(5):862-867.
52. Swain J.E., Scahill L., Lombroso P.J., King R.A., Leckman J.F. Tourette syndrome and tic disorders: a decade of progress. Journal of the American Academy of Child and Adolescent Psychiatry 2007, 46(8):947-968.
53. Tourette's Syndrome Study Group Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002, 58(4):527-536.
54. Verdellen C.W., Hoogduin C.A., Kato B.S., Keijsers G.P., Cath D.C., Hoijtink H.B. Habituation of premonitory sensations during exposure and response prevention treatment in Tourette's syndrome. Behavior Modification 2008, 32(2):215-227.
55. Verdellen C.W., Hoogduin C.A., Keijsers G.P. Tic suppression in the treatment of Tourette's syndrome with exposure therapy: the rebound phenomenon reconsidered. Movement Disorders 2007, 22(11):1601-1606.
56. Verdellen C.W., Keijsers G.P., Cath D.C., Hoogduin C.A. Exposure with response prevention versus habit reversal in Tourettes's syndrome: a controlled study. Behaviour Research and Therapy 2004, 42(5):501-511.
57. Waldon K., Hill J., Termine C., Balottin U., Cavanna A.E. Trials of pharmacological interventions for Tourette syndrome: a systematic review. Behavioural Neurology 2012.
58. Walkup J.T., Rosenberg L.A., Brown J., Singer H.S. The validity of instruments measuring tic severity in Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry 1992, 31(3):472-477.
59. Wang M., Ramos B.P., Paspalas C.D., Shu Y., Simen A., Duque A., et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007, 129(2):397-410.